Loading…
Veraxa Biotech AG - Post de-SPAC
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VRXA.
▼ -85.9% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $10.67 | $10.02 | |
| P/S | — | 64408.0x | — |
| P/B | — | — | 45.6x |
| EPS | — | -$0.20 | |
| Profit margin | — | -284359.22% | — |
| ROE | — | — | -90.59% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LUCDLucid Diagnostics Inc. | $0.99 | — | 17.4x | — | -556.27% | $189.31M |
| CNXUConexeu Sciences Inc. | $7.07 | — | 20.6x | — | — | $189.18M |
| AIRSAirsculpt Technologies, Inc. | $2.60 | — | 1.8x | — | -11.98% | $187.45M |
| ORGOOrganogenesis Holdings Inc. | $1.45 |
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
Company description provided by Yahoo Finance.
| — |
| 1.3x |
| — |
| -25.92% |
| $186.58M |
| FOCLEdap Tms SA | $4.31 | — | — | — | -265.67% | $198.06M |
| MSLESatellos Bioscience Inc. | $8.66 | — | 3.0x | — | -70.45% | $183.73M |